Eli Lilly | Salg Og Administrasjonskostnader



Selling And Administration Expenses Endring Dato
AbbVie USD 3.29B 562M 2025-03
Abbott USD 3.05B 144M 2025-03
ALKERMES USD 146.99M 3.39M 2024-12
Amgen USD 1.88B 253M 2024-12
AstraZeneca USD 3.59B 1.96B 2025-03
Baxter International USD 615M 16M 2024-12
Biogen USD 677.3M 99.6M 2024-12
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Drreddys Laboratories INR 21.59B 436M 2024-12
Eli Lilly USD 2.36B 62.3M 2025-03
Gilead Sciences USD 1.26B 603M 2025-03
GlaxoSmithKline GBP 2.06B 603M 2025-03
Glaxosmithkline GBP 2.7B 632M 2024-12
Indivior 132M 179M 2025-03
J&J USD 5.11B 1.34B 2025-03
Medtronic USD 2.72B 34M 2025-01
Merck USD 2.53B 319M 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Novartis USD 3.5B 368M 2024-12
Novo Nordisk 16.59B 501M 2024-09
Perrigo USD 234.8M 36.7M 2024-12
Pfizer USD 3.01B 1.27B 2025-03
Prestige Brands USD 64.13M 3.35M 2024-12
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Roche Holding CHF 3.61B 381M 2024-12
Sanofi EUR 2.22B 980M 2025-03
Sanofi EUR 1.24B 1.44B 2024-12
United Therapeutics USD 170.1M 7.6M 2025-03
Zoetis USD 625M 60M 2024-12



Eli Lilly Salg Og Administrasjonskostnader - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - May 2025.